Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics

Overview

Journal J Clin Exp Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2016 Dec 23

PMID 28003721

Citations 6

Authors

Amitkumar Patel

Anil Seetharam

Affiliations

Soon will be listed here.

Abstract

Primary Biliary Cholangitis is a progressive, autoimmune cholestatic liver disorder. Cholestasis with disease progression may lead to dyslipidemia, osteodystrophy and fat-soluble vitamin deficiency. Portal hypertension may develop prior to advanced stages of fibrosis. Untreated disease may lead to cirrhosis, hepatocellular cancer and need for orthotopic liver transplantation. Classically, diagnosis is made with elevation of alkaline phosphatase, demonstration of circulating antimitochondrial antibody, and if performed: asymmetric destruction/nonsupperative cholangitis of intralobular bile ducts on biopsy. Disease pathogenesis is complex and results from innate and adaptive (cell-mediated and humoral) responses that lead to inflammation of biliary duct epithelium. Ongoing damage is amplified and sustained through bile acid toxicity. Use of weight based (13-15mg/kg) ursodeoxycholic acid is well established in retarding disease progression and improving survival; however, is ineffective in achieving complete biochemical remission in many. Recently, a Farnesoid X Receptor agonist, obeticholic acid, has been approved for use. A number of ongoing clinical studies are underway to evaluate utility of fibric acid derivatives, biologics, antifibrotics, and stem cells as monotherapy or in combination with ursodeoxycholic acid for primary biliary cholangitis. The aim of this review is to discuss disease pathogenesis and highlight rationale/implications for both established and novel therapeutics.

Citing Articles

Cholestasis: exploring the triangular relationship of gut microbiota-bile acid-cholestasis and the potential probiotic strategies.

Yu L, Liu Y, Wang S, Zhang Q, Zhao J, Zhang H Gut Microbes. 2023; 15(1):2181930.

PMID: 36864554 PMC: 9988349. DOI: 10.1080/19490976.2023.2181930.

PPARα: A potential therapeutic target of cholestasis.

Ye X, Zhang T, Han H Front Pharmacol. 2022; 13:916866.

PMID: 35924060 PMC: 9342652. DOI: 10.3389/fphar.2022.916866.

Review: Pathogenesis of cholestatic liver diseases.

Yokoda R, Rodriguez E World J Hepatol. 2020; 12(8):423-435.

PMID: 32952871 PMC: 7475774. DOI: 10.4254/wjh.v12.i8.423.

Esophageal Ulcers in Primary Biliary Cholangitis: A Rare Cause of Hematemesis in the Setting of Portal Hypertension and Esophageal Varices.

Kolli S, Mori A, Moshenyat I Gastroenterology Res. 2018; 11(5):388-390.

PMID: 30344813 PMC: 6188036. DOI: 10.14740/gr1077w.

Exploring pathogenesis of primary biliary cholangitis by proteomics: A pilot study.

Deng C, Wang L, Fei Y, Hu C, Yang Y, Peng L World J Gastroenterol. 2018; 23(48):8489-8499.

PMID: 29358857 PMC: 5752709. DOI: 10.3748/wjg.v23.i48.8489.

References

Poupon R, Chretien Y, Poupon R, Ballet F, Calmus Y, DARNIS F . Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?. Lancet. 1987; 1(8537):834-6. DOI: 10.1016/s0140-6736(87)91610-2. View

Rodriguez-Ortigosa C, Cincu R, Sanz S, Ruiz F, Quiroga J, Prieto J . Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats. Gut. 2002; 50(5):701-6. PMC: 1773200. DOI: 10.1136/gut.50.5.701. View

KAPLAN M . Primary biliary cirrhosis. N Engl J Med. 1996; 335(21):1570-80. DOI: 10.1056/NEJM199611213352107. View

Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K . Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol. 2004; 10(6):894-8. PMC: 4727018. DOI: 10.3748/wjg.v10.i6.894. View

Leuschner M, Maier K, Schlichting J, Strahl S, Herrmann G, Dahm H . Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology. 1999; 117(4):918-25. DOI: 10.1016/s0016-5085(99)70351-3. View

Hirschfield G, Mason A, Luketic V, Lindor K, Gordon S, Mayo M . Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2014; 148(4):751-61.e8. DOI: 10.1053/j.gastro.2014.12.005. View

Arenas F, Hervias I, Uriz M, Joplin R, Prieto J, Medina J . Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest. 2008; 118(2):695-709. PMC: 2176189. DOI: 10.1172/JCI33156. View

Calmus Y, Gane P, Rouger P, Poupon R . Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology. 1990; 11(1):12-5. DOI: 10.1002/hep.1840110104. View

Corpechot C, Carrat F, Bonnand A, Poupon R, Poupon R . The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology. 2000; 32(6):1196-9. DOI: 10.1053/jhep.2000.20240. View

10.

Li M, Zheng H, Li T, Gao P, Zhang X, Liu D . Cytotoxic T-lymphocyte associated antigen-4 gene polymorphisms and primary biliary cirrhosis: a systematic review. J Gastroenterol Hepatol. 2012; 27(7):1159-66. DOI: 10.1111/j.1440-1746.2012.07118.x. View

11.

Angulo P, Jorgensen R, Keach J, Dickson E, Smith C, Lindor K . Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000; 31(2):318-23. DOI: 10.1002/hep.510310209. View

12.

Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon R, Poupon R . The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005; 128(2):297-303. DOI: 10.1053/j.gastro.2004.11.009. View

13.

Ali A, Sinakos E, Silveira M, Jorgensen R, Angulo P, Lindor K . Varices in early histological stage primary biliary cirrhosis. J Clin Gastroenterol. 2010; 45(7):e66-71. DOI: 10.1097/MCG.0b013e3181f18c4e. View

14.

Boonstra K, Beuers U, Ponsioen C . Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012; 56(5):1181-1188. DOI: 10.1016/j.jhep.2011.10.025. View

15.

Poupon R, Bonnand A, Chretien Y, Poupon R . Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology. 1999; 29(6):1668-71. DOI: 10.1002/hep.510290603. View

16.

Poupon R . Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol. 2012; 36 Suppl 1:S3-12. DOI: 10.1016/S2210-7401(12)70015-3. View

17.

Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C . Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008; 48(3):871-7. DOI: 10.1002/hep.22428. View

18.

Carey E, Ali A, Lindor K . Primary biliary cirrhosis. Lancet. 2015; 386(10003):1565-75. DOI: 10.1016/S0140-6736(15)00154-3. View

19.

Matsumoto T, Miyazaki H, Nakahashi Y, Hirohara J, Seki T, Inoue K . Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol Res. 2004; 30(3):125-136. DOI: 10.1016/j.hepres.2004.08.015. View

20.

. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51(2):237-67. DOI: 10.1016/j.jhep.2009.04.009. View